HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

glycinamide ribonucleotide

structure in first source
Also Known As:
beta-GAR
Networked: 24 relevant articles (2 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Gangjee, Aleem: 2 articles (10/2014 - 10/2011)
2. Hou, Zhanjun: 2 articles (10/2014 - 10/2011)
3. Matherly, Larry H: 2 articles (10/2014 - 10/2011)
4. Hanauske, Axel R: 2 articles (11/2004 - 06/2002)
5. George, Christina: 1 article (10/2014)
6. Wilson, Mike R: 1 article (10/2014)
7. Wallace, Adrianne: 1 article (10/2014)
8. Orr, Steven: 1 article (10/2014)
9. Golani, Lalit K: 1 article (10/2014)
10. Raghavan, Sudhir: 1 article (10/2014)

Related Diseases

1. Neuroblastoma
2. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
3. Neoplasms (Cancer)
4. Breast Neoplasms (Breast Cancer)
06/01/2002 - "In a phase II trial in patients with T3-4, N0-2 breast cancer, expression of thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase, p53, and c-erb-B2 (at the mRNA or protein level) is being examined before and 24 hours after the first dose of neoadjuvant pemetrexed and after three cycles of single-agent treatment to establish correlations of biomarker levels and changes with clinical outcome and toxicity. "
06/01/2002 - "Pemetrexed (Alimta; Eli Lilly and Co, Indianapolis, IN) is a novel antifolate/antimetabolite with activity in breast cancer and has well-defined molecular targets, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. "
11/01/2004 - "In a phase II trial of patients with T3/4, N0-2 breast cancer, expression of thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT), p53, and c-erb-B2 (at the mRNA or protein level) was examined in tumor biopsy specimens before and 24 hours after the first dose of pemetrexed and after three cycles of single-agent treatment to establish correlations of biomarker levels and changes with clinical outcome and toxicity. "
04/01/1999 - "LY231514, a multitargeted antifolate (MTA), was tested in combination with cisplatin, methotrexate, 5-fluorouracil, paclitaxel, docetaxel, doxorubicin, LY329201 (a glycinamide ribonucleotide formyltransferase [GARFT] inhibitor), and fractionated radiation therapy in vivo using EMT-6 mammary carcinoma, human HCT 116 colon carcinoma, and human H460 nonsmall cell lung carcinoma grown as xenografts in nude mice. "
5. Leukemia

Related Drugs and Biologics

1. pemetrexed (MTA)
2. thymidylate synthase-dihydrofolate reductase
3. 6R- 2',5'- thienyl- 5,10- dideazatetrahydrofolic acid
4. Thymidylate Synthase
5. Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
6. Messenger RNA (mRNA)
7. Methotrexate (Mexate)
8. Folic Acid Antagonists
9. Folic Acid (Vitamin M)
10. Transferases

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Drug Therapy (Chemotherapy)